$HCAT
Health Catalyst, Inc. Stock $hcat

$hcat Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000163642223000058 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$73.21M	$73.87M	$68.09M
YoY Change	3.65%	8.49%	21.92%
Cost Of Revenue	$39.27M	$37.69M	$33.67M
YoY Change	14.24%	11.92%	23.16%
Gross Profit	$33.95M	$36.18M	$34.42M
YoY Change	-6.38%	5.13%	20.72%
Gross Profit Margin	46.37%	48.98%	50.55%
Selling, General & Admin	$30.35M	$42.40M	$29.64M
YoY Change	-21.09%	43.05%	-3.34%
% of Gross Profit	89.4%	117.19%	86.13%
Research & Development	$17.40M	$17.08M	$17.15M
YoY Change	-4.15%	-0.38%	19.54%
% of Gross Profit	51.24%	47.21%	49.83%
Depreciation & Amortization	$10.74M	$3.200M	$2.300M
YoY Change	312.88%	39.13%	228.57%
% of Gross Profit	31.62%	8.84%	6.68%
Operating Expenses	$58.48M	$70.48M	$58.44M
YoY Change	-15.51%	20.6%	10.63%
Operating Profit	-$24.53M	-$34.91M	-$24.35M
YoY Change	-26.09%	43.4%	0.12%
Interest Expense	$2.084M	$1.793M	-$1.631M
YoY Change	-283.94%	-209.93%	-59.02%
% of Operating Profit
Other Income/Expense, Net	$6.000K	$5.000K	-$31.00K
YoY Change	-112.77%	-116.13%	-255.0%
Pretax Income	-$32.53M	-$33.12M	-$26.01M
YoY Change	-5.36%	27.34%	-8.0%
Income Tax	$85.00K	$69.00K	-$3.600M
% Of Pretax Income
Net Earnings	-$32.61M	-$33.19M	-$22.46M
YoY Change	-2.44%	47.79%	-20.84%
Net Earnings / Revenue	-44.55%	-44.93%	-32.98%
Basic Earnings Per Share	-$0.58	-$0.60	-$0.42
Diluted Earnings Per Share	-$0.58	-$0.60	-$0.54
COMMON SHARES
Basic Shares Outstanding	56.26M shares	55.81M shares	53.01M shares
Diluted Shares Outstanding	55.98M shares	55.48M shares	53.22M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$343.8M	$356.9M	$425.4M
YoY Change	-14.76%	-16.1%	59.69%
Cash & Equivalents	$115.7M	$133.5M	$198.4M
Short-Term Investments	$228.1M	$223.4M	$227.0M
Other Short-Term Assets	$14.74M	$15.73M	$14.45M
YoY Change	3.32%	8.86%	16.52%
Inventory
Prepaid Expenses
Receivables	$52.38M	$61.86M	$42.63M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$411.0M	$434.5M	$482.5M
YoY Change	-11.69%	-9.94%	48.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.85M	$26.44M	$24.89M
YoY Change	57.75%	6.24%	33.43%
Goodwill	$186.0M	$186.0M	$180.3M
YoY Change	0.0%	3.13%	67.25%
Intangibles	$79.04M	$84.41M	$112.2M
YoY Change	-27.82%	-24.75%	22.14%
Long-Term Investments
YoY Change
Other Assets	$5.083M	$4.790M	$4.421M
YoY Change	36.49%	8.35%	8.68%
Total Long-Term Assets	$312.0M	$317.8M	$342.4M
YoY Change	-9.83%	-7.2%	38.93%
TOTAL ASSETS
Total Short-Term Assets	$411.0M	$434.5M	$482.5M
Total Long-Term Assets	$312.0M	$317.8M	$342.4M
Total Assets	$722.9M	$752.3M	$824.9M
YoY Change	-10.9%	-8.8%	44.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.974M	$9.243M	$5.865M
YoY Change	40.12%	57.6%	26.78%
Accrued Expenses	$19.26M	$27.35M	$23.61M
YoY Change	-12.89%	15.83%	53.31%
Deferred Revenue	$59.53M	$65.91M	$61.80M
YoY Change	-2.23%	6.64%	19.69%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$86.76M	$102.5M	$92.65M
YoY Change	-3.93%	10.62%	-64.29%
LONG-TERM LIABILITIES
Long-Term Debt	$227.3M	$226.9M	$225.4M
YoY Change	0.67%	0.67%
Other Long-Term Liabilities	$19.00M	$123.0K	$115.0K
YoY Change	16001.69%	6.96%	-94.84%
Total Long-Term Liabilities	$246.3M	$227.0M	$225.5M
YoY Change	9.03%	0.67%	10012.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$86.76M	$102.5M	$92.65M
Total Long-Term Liabilities	$246.3M	$227.0M	$225.5M
Total Liabilities	$333.0M	$347.2M	$344.0M
YoY Change	-2.7%	0.91%	13.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.065B	-$1.032B	-$884.1M
YoY Change	16.06%	16.76%	17.25%
Common Stock			$53.00K
YoY Change			20.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$389.9M	$405.1M	$480.9M
YoY Change
Total Liabilities & Shareholders Equity	$722.9M	$752.3M	$824.9M
YoY Change	-10.9%	-8.8%	44.41%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$32.61M	-$33.19M	-$22.46M
YoY Change	-2.44%	47.79%	-20.84%
Depreciation, Depletion And Amortization	$10.74M	$3.200M	$2.300M
YoY Change	312.88%	39.13%	228.57%
Cash From Operating Activities	-$11.57M	-$5.580M	$1.158M
YoY Change	20.86%	-581.87%	-136.84%
INVESTING ACTIVITIES
Capital Expenditures	$4.802M	$425.0K	$356.0K
YoY Change	-200.0%	19.38%	-93.95%
Acquisitions		$0.00	$18.51M
YoY Change		-100.0%
Other Investing Activities	-$2.613M	$26.04M	$5.736M
YoY Change	-70.8%	353.91%	-87.15%
Cash From Investing Activities	-$7.415M	$22.65M	$1.656M
YoY Change	-46.08%	1267.69%	-95.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.202M	$93.00K	$2.388M
YoY Change	-36.77%	-96.11%	-62.95%
NET CHANGE
Cash From Operating Activities	-11.57M	-$5.580M	$1.158M
Cash From Investing Activities	-7.415M	$22.65M	$1.656M
Cash From Financing Activities	1.202M	$93.00K	$2.388M
Net Change In Cash	-17.79M	$17.17M	$5.201M
YoY Change	-16.98%	230.07%	-87.21%
FREE CASH FLOW
Cash From Operating Activities	-$11.57M	-$5.580M	$1.158M
Capital Expenditures	$4.802M	$425.0K	$356.0K
Free Cash Flow	-$16.38M	-$6.005M	$802.0K
YoY Change	243.02%	-848.75%	-108.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001636422
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38993
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTH CATALYST, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3337483
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10897 South River Front Parkway #300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South Jordan
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84095
CY2023Q1	dei	City Area Code CityAreaCode	801
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	708-6800
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	HCAT
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56260231	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133479000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116312000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	223448000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	247178000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	61862000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47970000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15728000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16335000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	434517000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	427795000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26441000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25928000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16161000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16658000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	84410000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	92189000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	185982000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	185982000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4790000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3734000	usd
CY2023Q1	us-gaap	Assets Assets	752301000	usd
CY2022Q4	us-gaap	Assets Assets	752286000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9243000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4424000	usd
CY2023Q1	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23953000	usd
CY2022Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	19691000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	65905000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	54961000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3394000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3434000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	102495000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	82510000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	226900000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	226523000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	189000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	105000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17448000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18017000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	123000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	121000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	347155000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	327276000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55843457	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55843457	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55261922	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55261922	shares
CY2023Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1437654000	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1424681000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1032213000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-999023000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-295000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-648000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	405146000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425010000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	752301000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	752286000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73868000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68087000	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	38304000	usd
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	33996000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18569000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20818000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17082000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17148000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23833000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8823000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10994000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11649000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	70478000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	58438000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-34914000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24347000	usd
CY2023Q1	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	-1793000	usd
CY2022Q1	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	1662000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-33121000	usd
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26009000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3551000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-33190000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55485000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53007000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55485000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53215000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-33190000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	348000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-118000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-78000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32837000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22654000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425010000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	727000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14054000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1808000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-33190000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	353000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	405146000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	522098000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1809000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18438000	usd
CY2022Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	2306000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2885000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-196000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	480909000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-33190000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13884000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18120000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10994000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11649000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8424000	usd
CY2023Q1	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-764000	usd
CY2022Q1	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-819000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1979000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-398000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	377000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	374000	usd
CY2023Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	1514000	usd
CY2022Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	200000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3598000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	19000	usd
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-49000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15405000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6019000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	420000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-437000	usd
CY2023Q1	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	7709000	usd
CY2022Q1	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	-4812000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11027000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4106000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	741000	usd
CY2023Q1	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-876000	usd
CY2022Q1	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-882000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5580000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1158000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	107100000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	80960000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	81070000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	56719000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	18509000	usd
CY2023Q1	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	2864000	usd
CY2022Q1	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	3261000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	98000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	463000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	425000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	356000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22649000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1656000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	727000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1809000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1174000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1509000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1808000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	930000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	93000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2388000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17167000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5201000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116312000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193227000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	133479000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198428000	usd
CY2023Q1	hcat	Noncash Or Part Noncash Acquisition Internal Use Software Acquired NoncashOrPartNoncashAcquisitionInternalUseSoftwareAcquired	855000	usd
CY2022Q1	hcat	Noncash Or Part Noncash Acquisition Internal Use Software Acquired NoncashOrPartNoncashAcquisitionInternalUseSoftwareAcquired	528000	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	171000	usd
CY2022Q1	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	318000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	75000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	0	usd
CY2022Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	2306000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2885000	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	885000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	66100000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates.</span></div>
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q1	hcat	Revenue From Subscriptions Contract Allowed Termination Period RevenueFromSubscriptionsContractAllowedTerminationPeriod	P1Y
CY2023Q1	hcat	Revenue From Subscriptions Contract Notice Required For Termination RevenueFromSubscriptionsContractNoticeRequiredForTermination	P90D
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1700000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	900000	usd
CY2022Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3700000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	55100000	usd
CY2023Q1	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	1800000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	1500000	usd
CY2023Q1	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P12M
CY2023Q1	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	3200000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	2600000	usd
CY2023Q1	hcat	Commission Payment Estimated Benefit Period CommissionPaymentEstimatedBenefitPeriod	P4Y
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	500000	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	400000	usd
CY2022Q1	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2023Q1	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2300000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1600000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1514000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	14000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3800000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1800000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	185982000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	185982000	usd
CY2022Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	196664000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
CY2022Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1700000	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	300000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	1000000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2200000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	112254000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	84410000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73868000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68087000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	197104000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	104915000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	92189000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7800000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9300000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45574000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43385000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19133000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17457000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26441000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25928000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	3200000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	2300000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3400000	usd
CY2022Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1300000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	344836000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	76000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	303000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	344609000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	362285000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	583000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	361710000	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	700000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	600000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8221000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12180000	usd
CY2023Q1	hcat	Accrued Legal Costs Current AccruedLegalCostsCurrent	10471000	usd
CY2022Q4	hcat	Accrued Legal Costs Current AccruedLegalCostsCurrent	0	usd
CY2023Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1067000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1837000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4194000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5674000	usd
CY2023Q1	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23953000	usd
CY2022Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	19691000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2023Q1	us-gaap	Share Price SharePrice	11.67
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Shares Outstanding SharesOutstanding	56257248	shares
CY2023Q1	us-gaap	Shares Issued SharesIssued	56257248	shares
CY2022Q4	us-gaap	Shares Outstanding SharesOutstanding	55764942	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	55764942	shares
CY2022Q4	hcat	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Non Recourse ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonRecourse	503020	shares
CY2023Q1	hcat	Stockholders Vote StockholdersVote	1	vote
CY2023Q1	us-gaap	Dividends Cash DividendsCash	0	usd
CY2022Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	40000000	usd
CY2023Q1	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	145027	shares
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	145027	shares
CY2023Q1	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1800000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1800000	usd
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	12.45
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	8400000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	29800000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33190000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22458000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55484835	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53006704	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33190000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22458000	usd
CY2023Q1	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	0	usd
CY2022Q1	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	-6104000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-33190000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28562000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55484835	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53006704	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	208326	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55484835	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53215030	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14762437	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14728515	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13884000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18120000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13884000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18120000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1748306	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.51
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97875	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.43
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14946	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.80
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1635485	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.77
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1507519	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1635485	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.77
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1507519	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1635375	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.76
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1507519	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	350210	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	33.48
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.137
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000	usd
CY2023Q1	hcat	Contract With Customer Liability Revenue Recognized Percentage ContractWithCustomerLiabilityRevenueRecognizedPercentage	0.39
CY2022Q1	hcat	Contract With Customer Liability Revenue Recognized Percentage ContractWithCustomerLiabilityRevenueRecognizedPercentage	0.45
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	128100000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.70
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73868000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68087000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-33121000	usd
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26009000	usd
CY2022Q1	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd

Files In Submission

Name	View Source	Status
0001636422-23-000058-index-headers.html	Edgar Link	pending
0001636422-23-000058-index.html	Edgar Link	pending
0001636422-23-000058.txt	Edgar Link	pending
0001636422-23-000058-xbrl.zip	Edgar Link	pending
exhibit101xofferletterdate.htm	Edgar Link	pending
exhibit102xofferletterdate.htm	Edgar Link	pending
exhibit311-q12023xcertific.htm	Edgar Link	pending
exhibit312-q12023xcertific.htm	Edgar Link	pending
exhibit321-q12023xcertific.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcat-20230331.htm	Edgar Link	pending
hcat-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hcat-20230331_cal.xml	Edgar Link	unprocessable
hcat-20230331_lab.xml	Edgar Link	unprocessable
hcat-20230331_def.xml	Edgar Link	unprocessable
hcat-20230331_pre.xml	Edgar Link	unprocessable
hcat-20230331_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCAT
Health Catalyst, Inc. Stock $hcat

2023 Q2 Form 10-Q Financial Statement

#000163642223000058 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT Health Catalyst, Inc. Stock $hcat

2023 Q2 Form 10-Q Financial Statement

#000163642223000058 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT
Health Catalyst, Inc. Stock $hcat